作者
Thierry André,Dominique Berton,Giuseppe Curigliano,Renaud Sabatier,Anna V. Tinker,Ana Oaknin,Susan Ellard,Filippo de Braud,Hendrik‐Tobias Arkenau,José Trigo,Adriano Gravina,Rebecca Kristeleit,Víctor Moreno,Cyril Abdeddaim,Yann Vano,Vanessa Samouëlian,Rowan Miller,Valentina Boni,Antonio Antón Torres,Lucy Gilbert,Jubilee Brown,Ninad Dewal,Christine Dabrowski,Grace Antony,Eleftherios Zografos,Jennifer Veneris,Susana Banerjee
摘要
Mismatch repair deficiency (dMMR) occurs in various cancers, and these tumors are attractive candidates for anti-programmed cell death 1 therapies, such as dostarlimab, a recently approved immune checkpoint inhibitor.
毛豆
cocolu
ceeray23
丰知然
VDC
Jason
彭于彦祖
模糊中正
tuanheqi
十七
卡卡
pluto
无名老大
36456657
我是站长才怪
iNk
sutharsons
方羽
5度转角
不配.
皖公网安备34019202002308
